Daniel E. Geffken - 08 Oct 2021 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)

Reporting relationship: Chief Financial Officer
Issuer ticker: CERO
Reported as of: 08 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Oct 2021, 19:35:11 UTC
Prior SEC filing: 05 Oct 2021
Next SEC filing: 01 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Chris Ehrlich, as attorney-in-fact

Key filing fact

Daniel E. Geffken filed Form 4 for PHOENIX BIOTECH ACQUISITION CORP. (CERO) on 12 Oct 2021.

Key facts

This page summarizes Daniel E. Geffken's Form 4 filing for PHOENIX BIOTECH ACQUISITION CORP. (CERO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Oct 2021, 19:35.

Change

Previous filing in this sequence was filed on 05 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PBAX transaction Derivative

Class B Common Stock

Other

Transaction value
Shares: +30,000
Change %
Price
Shares after: 30,000
Date: 08 Oct 2021
Ownership: By Phoenix Biotech Sponsor, LLC
Underlying class: Class A Common Stock
Underlying amount: 30,000
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date.

Footnote F2

Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC.

Footnote F3

The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose.